Search results
Showing 2551 to 2565 of 8238 results
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [TSID12299]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC
Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]
Awaiting development Reference number: GID-TA11928 Expected publication date: TBC
In development Reference number: GID-QS10197 Expected publication date: 27 February 2026
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]
Awaiting development Reference number: GID-TA11912 Expected publication date: TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]
Awaiting development Reference number: GID-TA11913 Expected publication date: TBC
In development Reference number: GID-QS10094 Expected publication date: 01 July 2026
Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]
Awaiting development Reference number: GID-TA11914 Expected publication date: TBC
Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]
Awaiting development Reference number: GID-TA11915 Expected publication date: TBC
We are listening to your views on this NICE guideline. Comments close 27 January 2026.
Ravulizumab for treating primary IgA nephropathy [TSID12313]
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [TSID12324]
Awaiting development Reference number: GID-TA11920 Expected publication date: TBC
Awaiting development Reference number: GID-TA11921 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC